In some embodiments, a cancer is "inhibited" if at least one symptom of the cancer is alleviated, stopped, slowed, or prevented

Compared to normal tissue, GLO-1 was significantly upregulated in 28 tumors, including GBM (Tumor: 6.73 0.48, Normal: 5.37 1.31, p = 6.7e75), GBMLGG (Tumor: 6.58 0.41, Normal: 5.37 1.31, p = 8.5e216), LGG (Tumor: 6.53 0.37, Normal: 5.37 1.31, p = 3.7e178), BRCA (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), EGFR (Tumor: 6.83 0.68, Normal: 5.37 1.31, p = 3.7e179), CESC (Tumor: 6.44 0.63, Normal: 5.91 0.21, p = 1.2e4), LUAD (Tumor: 6.49 0.68, Normal: 5.87 0.93, p = 3.5e42), ESCA (Tumor: 6.78 0.62, Normal: 5.25 1.26, p = 6.3e84), STES (Tumor: 6.44 0.68, Normal: 5.13 1.38, p = 3.6e165), COAD (Tumor: 6.40 0.52, Normal: 4.99 1.67, p = 2.6e90), COADREAD (Tumor: 6.43 0.55, Normal: 5.01 1.66, p = 1.9e102), PRAD (Tumor: 7.81 0.90, Normal: 6.52 1.03, p = 4.7e34), STAD (Tumor: 6.29 0.65, Normal: 4.75 1.64, p = 6.8e64), HNSC (Tumor: 6.49 0.60, Normal: 5.72 0.54, p = 9.7e15), LUSC (Tumor: 6.52 0.66, Normal: 5.87 0.93, p = 9.2e48), LIHC (Tumor: 5.86 0.76, Normal: 4.87 0.60, p = 9.8e38), WT (Tumor: 7.21 0.38, Normal: 6.07 1.49, p = 3.5e35), SKCM (Tumor: 6.14 0.83, Normal: 5.78 0.39, p = 4.1e11), BLCA (Tumor: 6.13 0.74, Normal: 5.78 0.33, p = 1.3e3), THCA (Tumor: 5.64 0.43, Normal: 5.29 0.92, p = 7.8e28), READ (Tumor: 6.50 0.62, Normal: 6.02 0.34, p = 4.8e3), OV (Tumor: 6.59 1.08, Normal: 6.11 0.26, p = 5.6e14), PAAD (Tumor: 5.58 0.46, Normal: 3.62 1.58, p = 1.0e53), TGCT (Tumor: 6.01 0.89, Normal: 4.47 0.63, p = 1.3e37), and UCS (Tumor: 6.72 0.60, Normal: 5.74 0.29, p = 5.2e-18)

10.1016/j.ejphar.2014.11.011 Eur
However, various stimuli, such as complement activation in the early stages of OA, pro-inflammatory cytokines, and in the later stages of OA a hypoxic environment, activate FLS
Several studies have reported that phenobarbital is an effective alternative to benzodiazepines in AWS
Impact of various central endoscopy reading models on treatment outcome in Crohns disease using data from the randomized, controlled, exploratory cohort arm of the BERGAMOT trial